Cargando…

Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical Trial

Background: In addition to supportive therapy, antiviral therapy is an effective treatment for coronavirus disease 2019 (COVID-19). Objective: To compare the efficacy and safety of favipiravir and umifenovir (Arbidol) to treat COVID-19 patients. Methods: We conducted a prospective, randomized, contr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chang, Zhang, Yi, Huang, Jianying, Yin, Ping, Cheng, Zhenshun, Wu, Jianyuan, Chen, Song, Zhang, Yongxi, Chen, Bo, Lu, Mengxin, Luo, Yongwen, Ju, Lingao, Zhang, Jingyi, Wang, Xinghuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443786/ https://www.ncbi.nlm.nih.gov/pubmed/34539392 http://dx.doi.org/10.3389/fphar.2021.683296

Ejemplares similares

Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19
por: Liu, Lei, et al.
Publicado: (2021)

Reply to Peng He, Xiaohui Wang, and Hao Li’s Letter to the Editor re: Yu Xiao, Kaiyu Qian, Yongwen Luo, et al. Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Renal Failure Patients: A Potential Covert Source of Infection. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.03.025
por: Xiao, Yu, et al.
Publicado: (2020)

EFEMP2 suppresses epithelial-mesenchymal transition via Wnt/β-catenin signaling pathway in human bladder cancer
por: Zhou, Qiang, et al.
Publicado: (2019)

Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Renal Failure Patients: A Potential Covert Source of Infection
por: Xiao, Yu, et al.
Publicado: (2020)

EFEMP2 suppresses epithelial-mesenchymal transition via Wnt/β-catenin signaling pathway in human bladder cancer: Erratum
por: Zhou, Qiang, et al.
Publicado: (2022)

Evaluation of Antiviral Efficacy of Ribavirin, Arbidol, and T-705 (Favipiravir) in a Mouse Model for Crimean-Congo Hemorrhagic Fever
por: Oestereich, Lisa, et al.
Publicado: (2014)

Multicenter, randomized controlled, open label evaluation of the efficacy and safety of arbidol hydrochloride tablets in the treatment of influenza-like cases
por: Bai, Xinfeng, et al.
Publicado: (2023)

A trial of arbidol hydrochloride in adults with COVID-19
por: Zhao, Jingya, et al.
Publicado: (2022)

Comprehensive genomic profiling of urothelial carcinoma cell lines reveals hidden research bias and caveats
por: Luo, Yongwen, et al.
Publicado: (2020)

Nosocomial SARS-CoV-2 infection among nurses in Wuhan at a single centre
por: Sun, Huimin, et al.
Publicado: (2020)

Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial
por: Li, Yueping, et al.
Publicado: (2020)

Favipiravir and Hydroxychloroquine Combination Therapy in Patients with Moderate to Severe COVID-19 (FACCT Trial): An Open-Label, Multicenter, Randomized, Controlled Trial
por: Bosaeed, Mohammad, et al.
Publicado: (2021)

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study()
por: Cai, Qingxian, et al.
Publicado: (2020)

Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice
por: Li, Hailong, et al.
Publicado: (2021)

Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
por: Udwadia, Zarir F., et al.
Publicado: (2021)

Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
por: Zhu, Zhen, et al.
Publicado: (2020)

The Antiviral Drug Arbidol Inhibits Zika Virus
por: Fink, Susan L., et al.
Publicado: (2018)

Arbidol as a broad-spectrum antiviral: An update
por: Blaising, Julie, et al.
Publicado: (2014)

Arbidol: The current demand, strategies, and antiviral mechanisms
por: Kang, Yue, et al.
Publicado: (2023)

Real-world experience of arbidol for Omicron variant of SARS-CoV-2
por: Zhao, Jingya, et al.
Publicado: (2023)

Efficacy of Early Combination Therapy With Lianhuaqingwen and Arbidol in Moderate and Severe COVID-19 Patients: A Retrospective Cohort Study
por: Fang, Jie, et al.
Publicado: (2020)

An Open Label Randomized Controlled Trial of Ivermectin Plus Favipiravir-Based Standard of Care versus Favipiravir-Based Standard of Care for Treatment of Moderate COVID-19 in Thailand
por: Sarojvisut, Phahol, et al.
Publicado: (2023)

Identification of 9 key genes and small molecule drugs in clear cell renal cell carcinoma
por: Luo, Yongwen, et al.
Publicado: (2019)

Identification of a prognostic gene signature based on an immunogenomic landscape analysis of bladder cancer
por: Luo, Yongwen, et al.
Publicado: (2020)

Effectiveness of Arbidol for COVID-19 Prevention in Health Professionals
por: Yang, Chunguang, et al.
Publicado: (2020)

Beneficial effect of Arbidol in the management of COVID-19 infection
por: Jie, Xiong, et al.
Publicado: (2021)

PIONEER trial: favipiravir to treat moderate COVID-19
por: Shalhoub, Sarah
Publicado: (2023)

Efficacy of Favipiravir in treatment of mild & moderate COVID-19 infection in Nepal: a multi-center, randomized, open-labelled, phase III clinical trial
por: Adhikari, P., et al.
Publicado: (2022)

Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients
por: Chen, Ping-Jen, et al.
Publicado: (2021)

Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial
por: Zhao, Hong, et al.
Publicado: (2021)

Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir
por: Guner, Rahmet, et al.
Publicado: (2021)

Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial
por: Wu, Shipo, et al.
Publicado: (2021)

Synthesis and biological activity of water-soluble polymer complexes of arbidol
por: Eropkin, M. Yu., et al.
Publicado: (2010)

Efficacy of arbidol in COVID-19 patients: A retrospective study
por: Wei, Shuo, et al.
Publicado: (2021)

Arbidol is associated with increased in-hospital mortality among 109 patients with severe COVID-19: A multicenter, retrospective study
por: Zhou, Xianlong, et al.
Publicado: (2021)

Inhibition of MELK produces potential anti‐tumour effects in bladder cancer by inducing G1/S cell cycle arrest via the ATM/CHK2/p53 pathway
por: Chen, Song, et al.
Publicado: (2019)

Favipiravir Effectiveness and Safety in Hospitalized Moderate-Severe COVID-19 Patients: Observational Prospective Multicenter Investigation in Saudi Arabia
por: Al-Muhsen, Saleh, et al.
Publicado: (2022)

Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size
por: Zhao, Hong, et al.
Publicado: (2021)

Clinical and immunological characteristics in COVID-19 convalescent patients
por: Su, Zhiying, et al.
Publicado: (2021)

Letter to the editor on “Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial” by Udwadia et al
por: Medisetty, Mahender Kumar, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_a6c42riqhfudmie4lt51nr37us